◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Madrigal Pharmaceuticals Inc (MDGL) Net Income 2006–TTM

Name: Madrigal Pharmaceuticals Inc (MDGL) net income history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Madrigal Pharmaceuticals Inc annual net income for fiscal TTM was -$325 million, a decrease of 12.8% from -$288 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

MDGL Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Net Income	($325M)	($288M)	($466M)	($374M)	($295M)	($241M)	($197M)	($73M)	($33M)	($31M)	($26M)	($7M)	($86M)	($90M)	($63M)	($47M)	($37M)	$79M	($93M)	($63M)	($57M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MDGL Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	($58M)	($94M)	($59M)	($114M)	($42M)	($73M)	($59M)	($107M)	($152M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

SMMT Net Income — Summit Therapeutics PLC
BBIO Net Income — BridgeBio Pharma Inc
HALO Net Income — Halozyme Therapeutics Inc
BMRN Net Income — Biomarin Pharmaceutical Inc
CORT Net Income — Corcept Therapeutics Incorporated
AXSM Net Income — Axsome Therapeutics Inc

More MDGL metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All MDGL financial statements → Interactive MDGL charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.